Terms: = Pancreatic cancer AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566 AND Treatment
22 results:
1. Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma.
Lei Z; Ma W; Si A; Zhang Y; Yang F; Yu Q; Tang H; Xiao Q; Zhou J; Wang K; Tang Y; Han T; Yin G; Chen J; Liu X; Zhao H; Yu D; Luo T; Wang Q; Yan M; Mao X; Li J; Wang K; Li J; Zeng Y; Ding D; Chen T; Wu X; Xia Y; Wang K; Guo W; Zhu G; Gao S; Hüser N; Lau WY; Song T; Cheng S; Shen F; Cheng Z
Aliment Pharmacol Ther; 2023 Sep; 58(6):611-622. PubMed ID: 37349908
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and Safety of Radiofrequency Ablation Plus Stent Versus Stent-alone treatments for Malignant Biliary Strictures: A Systematic Review and Meta-analysis.
Khizar H; Hu Y; Wu Y; Ali K; Iqbal J; Zulqarnain M; Yang J
J Clin Gastroenterol; 2023 Apr; 57(4):335-345. PubMed ID: 36628465
[TBL] [Abstract] [Full Text] [Related]
3. Machine Learning Predictive Model to Guide treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery.
Famularo S; Donadon M; Cipriani F; Fazio F; Ardito F; Iaria M; Perri P; Conci S; Dominioni T; Lai Q; La Barba G; Patauner S; Molfino S; Germani P; Zimmitti G; Pinotti E; Zanello M; Fumagalli L; Ferrari C; Romano M; Delvecchio A; Valsecchi MG; Antonucci A; Piscaglia F; Farinati F; Kawaguchi Y; Hasegawa K; Memeo R; Zanus G; Griseri G; Chiarelli M; Jovine E; Zago M; Abu Hilal M; Tarchi P; Baiocchi GL; Frena A; Ercolani G; Rossi M; Maestri M; Ruzzenente A; Grazi GL; Dalla Valle R; Romano F; Giuliante F; Ferrero A; Aldrighetti L; Bernasconi DP; Torzilli G;
JAMA Surg; 2023 Feb; 158(2):192-202. PubMed ID: 36576813
[TBL] [Abstract] [Full Text] [Related]
4. Impact of hemolysis on multi-OMIC pancreatic biomarker discovery to derisk biomarker development in precision medicine studies.
Searfoss R; Shah P; Ofori-Mensa K; Bussberg V; Tolstikov V; Greenwood B; Li H; Richardson K; Miller GM; DeCicco C; Granger E; Rodrigues LO; Grund EM; Moser AJ; Sarangarajan R; Narain NR; Kiebish MA
Sci Rep; 2022 Jan; 12(1):1186. PubMed ID: 35075163
[TBL] [Abstract] [Full Text] [Related]
5. Adjuvant Radiotherapy in Patients With pancreatic Adenocarcinoma. Is It Still Appealing in Clinical Trials? A Meta-analysis and Review of the Literature.
Pasqualetti F; Sainato A; Morganti R; Laliscia C; Vasile E; Gonnelli A; Montrone S; Gadducci G; Giannini N; Coccia N; Fuentes T; Zanotti S; Falconi M; Paiar F
Anticancer Res; 2021 Oct; 41(10):4697-4704. PubMed ID: 34593417
[TBL] [Abstract] [Full Text] [Related]
6. Lutetium oxodotreotide (
Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
[TBL] [Abstract] [Full Text] [Related]
7. Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta-analysis.
Burasakarn P; Higuchi R; Nunobe S; Kanaji S; Eguchi H; Okada KI; Fujii T; Nagakawa Y; Kanetaka K; Yamashita H; Yamada S; Kuroda S; Aoyama T; Akahori T; Nakagawa K; Yamamoto M; Yamaue H; Sho M; Kodera Y;
Int J Clin Oncol; 2021 Mar; 26(3):450-460. PubMed ID: 33386555
[TBL] [Abstract] [Full Text] [Related]
8. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for treatment of Metastatic pancreatic cancer: Using Korean pancreatic cancer (K-PaC) Registry.
Lee JC; Woo SM; Shin DW; Kim J; Yang SY; Kim MJ; Kim JW; Kim JW; Lee WJ; Cha HS; Park P; Kim J; Hwang JH
Am J Clin Oncol; 2020 Sep; 43(9):654-659. PubMed ID: 32889836
[TBL] [Abstract] [Full Text] [Related]
9. Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism.
Costa OS; Kohn CG; Kuderer NM; Lyman GH; Bunz TJ; Coleman CI
Blood Adv; 2020 Sep; 4(17):4045-4051. PubMed ID: 32853381
[TBL] [Abstract] [Full Text] [Related]
10. cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy.
Zhang YP; Bao ZW; Wu JB; Chen YH; Chen JR; Xie HY; Zhou L; Wu J; Zheng SS
Technol Cancer Res Treat; 2020; 19():1533033820944274. PubMed ID: 32715976
[TBL] [Abstract] [Full Text] [Related]
11. Identification of new candidate genes and signalling pathways associated with the development of neuroendocrine pancreatic tumours based on next generation sequencing data.
Kit OI; Trifanov VS; Petrusenko NA; Gvaldin DY; Kutilin DS; Timoshkina NN
Mol Biol Rep; 2020 Jun; 47(6):4233-4243. PubMed ID: 32451928
[TBL] [Abstract] [Full Text] [Related]
12. Estimates of Overall Survival in Patients With cancer Receiving Different treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
Petito LC; García-Albéniz X; Logan RW; Howlader N; Mariotto AB; Dahabreh IJ; Hernán MA
JAMA Netw Open; 2020 Mar; 3(3):e200452. PubMed ID: 32134464
[TBL] [Abstract] [Full Text] [Related]
13. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract] [Full Text] [Related]
14. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
[TBL] [Abstract] [Full Text] [Related]
15. Cost-effectiveness and clinical efficacy of biliary stents in patients undergoing neoadjuvant therapy for pancreatic adenocarcinoma in a randomized controlled trial.
Gardner TB; Spangler CC; Byanova KL; Ripple GH; Rockacy MJ; Levenick JM; Smith KD; Colacchio TA; Barth RJ; Zaki BI; Tsapakos MJ; Gordon SR
Gastrointest Endosc; 2016 Sep; 84(3):460-6. PubMed ID: 26972022
[TBL] [Abstract] [Full Text] [Related]
16. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
An SG; Kim DU; Song GA; Jang AL
Korean J Gastroenterol; 2014 Dec; 64(6):356-63. PubMed ID: 25530587
[TBL] [Abstract] [Full Text] [Related]
17. Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Qi WX; Tang LN; He AN; Yao Y; Shen Z
Respir Med; 2013 Aug; 107(8):1280-3. PubMed ID: 23810268
[TBL] [Abstract] [Full Text] [Related]
18. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
Yi JH; Lee J; Park SH; Lee KT; Lee JK; Lee KH; Choi DW; Choi SH; Heo JS; Lim DH; Park YS; Lim HY; Kang WK; Park K; Park JO
Oncology; 2011; 80(3-4):175-80. PubMed ID: 21701231
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells.
Hong YB; Kang HJ; Kim HJ; Rosen EM; Dakshanamurthy S; Rondanin R; Baruchello R; Grisolia G; Daniele S; Bae I
Exp Mol Med; 2009 Mar; 41(3):151-60. PubMed ID: 19293634
[TBL] [Abstract] [Full Text] [Related]
20. [Intra-arterial infusion chemotherapy for advanced cancer--40 years of experience].
Miura T
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1618-22. PubMed ID: 16315888
[TBL] [Abstract] [Full Text] [Related]
[Next]
